Lowe syndrome

Lowe syndrome is an X-linked disorder characterized by ocular findings, intellectual disability, and renal manifestations.  Genetic testing can help establish a diagnosis in affected patients, as well as carrier status in females.  

Downloads

Quick Reference
Test Code 4600
Turnaround Time (TAT) 2-4 weeks
Number of Genes 1
Specimen Requirements Click here

Ordering Options

Mutation Detection Rate

This test can detect >99.9% of described mutations in OCRL, when present (analytic sensitivity).

Test Description

Our Lowe syndrome genetic testing includes next generation sequencing (NGS) and deletion/duplication analysis of the OCRL gene.  Genomic deoxyribonucleic acid (gDNA) is isolated from the patient’s specimen using a standardized kit and quantified. Sequence enrichment of the targeted coding exons and adjacent intronic nucleotides is carried out by a bait-capture methodology using long biotinylated oligonucleotide probes, followed by polymerase chain reaction (PCR) and NGS. Sanger sequencing is performed for any regions missing, or with insufficient read depth coverage for reliable heterozygous variant detection. Reportable small insertions and deletions, potentially homozygous variants, variants in regions complicated by pseudogene interference, and single nucleotide variant calls not satisfying 100x depth of coverage and 40% het ratio thresholds are verified by Sanger sequencing.This assay targets all coding domains, and well into the flanking 5’ and 3’ ends of all the introns and untranslated regions. Gross deletion/duplication analysis is performed utilizing a targeted chromosomal microarray.

 

1. Mu W, et al. Sanger confirmation is required to achieve optimal sensitivity and specificity in next-generation sequencing panel testing. J Mol Diagn. 2016. 18(6):923-932.

View Full Menu

Search Results

Start your search...